RC:
The brilliant concept of Judah Folkman's (I
think he deserves a Nobel for Medicine) that
cutting the fuel-line of cancer cells, i.e.
by inhibiting its blood supply, is a viable
alternative to cytoreductive therapies for cancer
has taken firm root by now, although it took
almost 30 years from the time it was first proposed
(See "Tumor Angiogenesis:Therapeutic Implications.
New Eng J Med 1971:285 pp 1182-1186). When I
first embraced the idea and used this approach
with relatively primitive agents (alpha-interferon,
tetracyclines, shark's cartilage) in the late
'90s, I was very hopeful but yet did not see
dramatic results. Much hoopla has been supplanted
by realism: while on one hand we know much more
today than just a few years ago about angiogenesis
and its control, we have also awakened to the
reality that anti-angiogenesis alone (especially
with single agents) usually does not do the
job of stopping cancer growth. There are many
"alternatives" in this arena: from off-label
drugs such as cox-2 inhibitors to investigational
agents such as the copper-chelator tetrathiomolybdate
and many many supplements and herbs which have
been found to have antiangiogenic effects in
vitro.
Those interested in this area should read
the saga of this concept's development as chronicled
in the biography
of the maverick scientist-physician Judah Folkman.
For a beautiful introduction to angiogenesis
and cancer, the online article by Steven Brem
MD at the Mofitt in "Angiogenesis
and Cancer Control: From Concept to Therapeutic
Trial."
Many many agents (See growing and partial list
below!) of all kinds have antiangiogenic activity
although some of them are impractical or toxic
to use (Squalamine, Suramin), others are weak
(spironolactone), and still others are not yet
clinically established. Some agents (eg shark's
cartilage) stirred much hope but proved to be
unremarkable at the end.
Angiogenesis may not be as powerful as we hoped
but has proven clinial efficacy (as in the cases
of the new drugs targeting EGFR Iressa and Avastin),
but they are not as toxic as cytoreductive therapies
and have broad applicability to both solid and
hematologic tumors. Again, in concert with a
central theme of this site, I firmly believe
that a cocktail approach to angiogenesis (which
involves many biological switches and pathways)
and indeed a combined multi-tiered cocktail
approach to cancer combining anti-angiogenesis
and apoptosis and immunotherapy may be the ultimate
goal.
Potentially useful antiangiogenic agents include:
2-methoxy-estradiol
biphosphonates
captopril
Chinese herbs (such as Thunder God Vine)
Cox-2 inhibitors (e.g. celebrex)
cromolyn sodium (Nasalcrom)
cyclosporin
curcumin
ECGC
heparins
interferons
metronomic chemotherapy
neomycin
omega-3 fatty acids
penicillamine
PSP
retinoids
spironolactone
squalamine
steroids
suramin
tetracyclines
tetrathiomolybdate
thalidomide
trientine (Syprine)
Vitamin E's
|